The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: The California Cancer Registry, 1999-2004

Cancer

Volumn 112, Issue 4, 2008, Pages 737-747

  Brown, Monica ^a,e   Tsodikov, Alex ^b   Bauer, Katrina R ^a   Parise, Carol A ^c   Caggiano, Vincent ^c,d  

^a PUBLIC HEALTH INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Sutter Institute for Medical Research   (United States)

^d Sutter Medical Center   (United States)

^e Cancer Surveillance Program   (United States)

Author keywords

Breast neoplasms; Estrogen; Ethnic groups; Health disparities; Human epidermal growth factor receptor 2 neu; Progesterone; Receptors; Survival analysis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AFRICAN AMERICAN; ARTICLE; ASIAN; BREAST CANCER; CANCER GRADING; CANCER INVASION; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; DEMOGRAPHY; ETHNICITY; FEMALE; HISPANIC; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PACIFIC ISLANDER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RACE; REGRESSION ANALYSIS; RISK FACTOR; SOCIOECONOMICS; UNITED STATES;

AFRICAN AMERICANS; ALGORITHMS; ASIAN AMERICANS; BREAST NEOPLASMS; CALIFORNIA; FEMALE; HISPANIC AMERICANS; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGISTRIES; REGRESSION ANALYSIS; SOCIAL CLASS; SURVIVAL ANALYSIS;

EID: 39049164069     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23243     Document Type: Article

References (82)

1. American Cancer Society, California Division and Public Health Institute, California Cancer Registry. California Facts and Figures 2007. Oakland, Calif: American Cancer Society, Division; 2006.
2. Campleman S, Curtis R. Demographic aspects of breast cancer incidence and mortality in California, 1988-1999. In: Morris C, Kwong SL, eds. Breast Cancer in California, 2003, vol July. Sacramento, Calif: California Department of Health Services, Cancer Surveillance Section; 2004.
3. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005;97:439-448.
4. Jatoi I, Anderson WF, Rao SR, Devesa SS. Breast cancer trends among black and white women in the United States. J Clin Oncol. 2005;23:7836-7841.
5. Shavers VL, Harlan LC, Stevens JL. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer. 2003;97:134-147.
6. Jayasinghe UW, Taylor R, Boyages J. Is age at diagnosis an independent prognostic factor for survival following breast cancer? Aust N Z J Surg. 2005;75:762-767.
7. Swanson GM, Lin CS. Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment. J Natl Cancer Inst Monogr. 1994;16:69-77.
8. Hartley MC, McKinley BP, Rogers EA, et al. Differential expression of prognostic factors and effect on survival in young (≤40) breast cancer patients: a case-control study. Am Surg. 2006;72:1189-1194; discussion 1194-1195.
9. Jmor S, Al-Sayer H, Heys SD, Payne S, Miller I, Ah-See A, et al. Breast cancer in women aged 35 and under: prognosis and survival. J R Coll Surg Edinburgh. 2002;47:693-699.
10. Frost F, Tollestrup K, Hunt WC, Gilliland F, Key CR, Urbina CE. Breast cancer survival among New Mexico Hispanic, American Indian, and non-Hispanic white women (1973-1992). Cancer Epidemiol Biomarkers Prev. 1996;5:861-866.
11. Campbell JB. Breast cancer-race, ethnicity, and survival: a literature review. Breast Cancer Res Treat. 2002;74:187-192.
12. Gordon NH. Socioeconomic factors and breast cancer in black and white Americans. Cancer Metastasis Rev. 2003;22: 55-65.
13. Field TS, Buist DS, Doubeni C, et al. Disparities and survival among breast cancer patients. J Natl Cancer Inst Monogr. 2005;35:88-95.
14. Esteva FJ, Sahin AA, Cristofanilli M, Arun B, Hortobagyi GN. Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol. 2002;12:319-328.
15. Joslyn SA. Hormone receptors in breast cancer: racial differences in distribution and survival. Breast Cancer Res Treat. 2002;73:45-59.
16. Ademuyiwa FO, Olopade OI. Racial differences in genetic factors associated with breast cancer. Cancer Metastasis Rev. 2003;22:47-53.
17. Huang HJ, Neven P, Drijkoningen M, et al. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. Breast Cancer Res Treat. 2005;91:81-87.
18. Hlupic L, Jakic-Razumovic J, Bozikov J, Coric M, Belev B, Vrbanec D. Prognostic value of different factors in breast carcinoma. Tumori. 2004;90:112-119.
19. Wu Y, Khan H, Chillar R, Vadgama JV. Prognostic value of plasma HER-2/neu in African American and Hispanic women with breast cancer. Int J Oncol. 1999;14:1021-1037.
20. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989;7:1120-1128.
21. Kroger N, Milde-Langosch K, Riethdorf S, et al. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res. 2006;12:159-168.
22. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Ann Oncol. 2005;16:1569-1583.
23. Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A. HER2 as a prognostic factor in breast cancer. Oncology. 2001;61(suppl 2):67-72.
24. Luftner D, Jung A, Schmid P, et al. Up-regulation of HER-2/neu by ovarian ablation: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patients. Breast Cancer Res Treat. 2003;80:245-255.
25. Dowsett M, Cooke T, Ellis I, et al. Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer. 2000;36:170-176.
26. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers [electronic resource]. Breast Cancer Res. 2007;9:R16.
27. Early Breast Cancer Trialist's Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.
28. Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer. 2005;103:2241-2251.
29. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
30. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726.
31. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
32. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-10874.
33. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-2502.
34. Collins LC, Schnitt SJ, Colditz GA, et al. Risk factors for luminal, HER2, and basal-like breast cancer subtypes: results from a tissue microarray-based analysis of invasive breast cancers from women enrolled in the Nurses' Health Study [Abstract 5041]. Breast Cancer Res Treat. 2006;100(suppl 1):S275.
35. Rakha EA, El-Rehim DA, Paish C, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer. 2006;42:3149-3156.
36. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005;11:5175-5180.
37. Mountain JL, Risch N. Assessing genetic contributions to phenotypic differences among 'racial' and 'ethnic' groups. Nat Genet. 2004;36(11 suppl):S48-S53.
38. Lund MB, Eley JW, Brawley OW, Liff JM, Coates RJ, Porter PL. Racial differences in triple negative breast tumors among women in Atlanta [abstract]. Proc Am Assoc Cancer Res. 2006;47;LB-4.
39. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007;109:1721-1128.
40. Caggiano V, Brown M, Bauer KR, Tsodikov A, Parise C. Incidence, risk factors, and survival among triple negative phenotypic (estrogen receptor, progesterone receptor, and HER2 negative) breast cancers in California, 1999-2003 [Abstract 6057]. Breast Cancer Res Treat. 2006;100(suppl 1):S275.
41. California Department of Health Services, Cancer Surveillance Section.Cancer Reporting in California: Standards for Automated Reporting. California cancer reporting system Standards, vol II. Sacramento, Calif: California Department of Health Services, Cancer Surveillance Section; 2006.
42. Percy C, Fritz A, Jack A, et al. International Classification of Diseases for Oncology, 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
43. Bauer KR, Brown M, Creech C, Schlag NC, Caggiano V. Data quality assessment of HER2 in the Sacramento Region of the California Cancer Registry. J Registry Manage. 2007;34:4-7.
44. Fritz A. Recording Tumor Markers in Collaborative Staging System Site-Specific Factors, vol 2006. 2005. Available at URL: http://ccrcal.org/PDF/ ATTACH-TumormMarkers-6-06.pdf. Accessed December 18, 2007.
45. DAKO. HERCEPTest® Information Web site. Summary of Procedure. Available at URL: www.dakousa.com/proddownloadpackageinsert.pdf?objectid= 114969002. Accessed December 18, 2007.
46. Vysis, Inc. PathVysion®: HER-2 DNA Probe Kit [package insert]. Downers Grove, Ill: Vysis, Inc.; 2002.
47. Stewart SL, Swallen KC, Glaser SL, Horn-Ross PL, West DW. Comparison of methods for classifying Hispanic ethnicity in a population-based cancer registry. Am J Epidemiol. 1999;149:1063-1071.
48. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 2001;12:703-711.
49. Greene FL, Page DL, Fleming ID, et al., eds. AJCC Cancer Staging Manual, 6th ed. New York, NY: Springer-Verlag; 2002.
50. Fritz A, Ries L, eds. SEER Extent of Disease 1998, Codes and Coding Instructions, 3rd ed. Bethesda, Md: National Cancer Institute, National Institutes of Health; 1998.
51. Collaborative Staging Task Force of the American Joint Committee on Cancer. Collaborative Staging Manual and Coding Instructions, version 01.03.00. Jointly published: Chicago, Ill; American Joint Committee on Cancer; Bethesda, Md, U.S. Department of Health and Human Services; 2004.
52. Seiffert JE, National Cancer Institute (US). SEER Program. Comparative Staging Guide for Cancer. Bethesda, Md: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute; 1993.
53. Fleiss JL, Levin BA, Paik MC. Statistical Methods for Rates and Proportions, 3rd ed. Hoboken, NJ: Wiley-Interscience; 2003.
54. Broet P, De Rycke Y, Tubert-Bitter P, Lellouch J, Asselain B, Moreau T. A semiparametric approach for the 2-sample comparison of survival times with long-term survivors. Biometrics. 2001;57:844-852.
55. Tsodikov A. A proportional hazards model taking account of long-term survivors. Biometrics. 1998;54:1508-1516.
56. Tsodikov AD, Ibrahim JG, Yakovlev AJ. Estimating cure rates from survival data: an alternative to two-component mixture models. J Am Stat Assoc. 2003;98:1063-1078.
57. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181-187.
58. Fisher B, Slack NH, Bross ID. Cancer of the breast: size of neoplasm and prognosis. Cancer. 1969;24:1071-1080.
59. Koscielny S, Tubiana M, Le MG, et al. Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer. 1984;49:709-715.
60. Cunningham JE, Butler WM. Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis. Breast Cancer Res Treat. 2004;88:161-176.
61. Menard S, Casalini P Campiglio M, Pupa S, Agresti R, Tagliabue E. HER2 overexpression in various tumor types, focusing on its relationship to the development of invasive breast cancer. Ann Oncol. 2001;12(suppl 1):S15-S19.
62. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418-8423.
63. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100:10393-10398.
64. Chu KC, Lamar CA, Freeman HP. Racial disparities in breast carcinoma survival rates: separating factors that affect diagnosis from factors that affect treatment. Cancer. 2003;97:2853-2860.
65. Newman LA. Breast cancer in African-American women. Oncologist. 2005;10:1-14.
66. Ries L, Eisner M, Kosary M. SEER Cancer Statistics Review, 1975-2000. Bethesda, Md: National Cancer Institute; 2003.
67. Woods LM, Rachet B, Coleman MP. Origins of socio-economic inequalities in cancer survival: a review. Ann Oncol. 2006;17:5-19.
68. Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst. 1994;86:705-712.
69. Boyer-Chammard A, Taylor TH, Anton-Culver H. Survival differences in breast cancer among racial/ethnic groups: a population-based study. Cancer Detect Prev. 1999;23:463-473.
70. El-Tamer MB, Wait RB. Age at presentation of African-American and Caucasian breast cancer patients. J Am Coll Surg. 1999;188:237-240.
71. Aziz H, Hussain F, Sohn C, et al. Early onset of breast carcinoma in African American women with poor prognostic factors. Am J Clin Oncol. 1999;22:436-440.
72. Boyle T, McPadden E. Breast cancer presents at an earlier age in Mexican American women. Breast J. 2004;10:462-464.
73. Colon E, Reyes JS, Gonzalez Keelan C, Climent-Peris C. Prevalence of steroid receptors and HER 2/neu in breast cancer biopsies of women living in Puerto Rico. P R Health Sci J. 2002;21:299-303.
74. Hsu JL, Glaser SL, West DW. Racial/ethnic differences in breast cancer survival among San Francisco Bay Area women. J Natl Cancer Inst. 1997;89:1311-1312.
75. Ayanian JZ, Kohler BA, Abe T, Epstein AM. The relation between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med. 1993;329:326-331.
76. Breen N, Wesley MN, Merrill RM, Johnson K. The relationship of socio-economic status and access to minimum expected therapy among female breast cancer patients in the National Cancer Institute Black-White Cancer Survival Study. Ethn Dis. 1999;9:111-125.
77. Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst. 2002;94:490-496.
78. Brawley OW. Disaggregating the effects of race and poverty on breast cancer outcomes. J Natl Cancer Inst. 2002;94:471-473.
79. O'Malley CD, Le GM, Glaser SL, Shema SJ, West DW. Socioeconomic status and breast carcinoma survival in 4 racial/ethnic groups: a population-based study. Cancer. 2003;97:1303-1311.
80. Yood MU, Johnson CC, Blount A, et al. Race and differences in breast cancer survival in a managed care population. J Natl Cancer Inst. 1999;91:1487-1491.
81. Franzini L, Williams AF, Franklin J, Singletary SE, Theriault RL. Effects of race and socioeconomic status on survival of 1,332 black, Hispanic, and white women with breast cancer. Ann Surg Oncol. 1997;4:111-118.
82. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.